Guardant Reveal
Tissue-free ctDNA MRD/recurrence and therapy-response monitoring test with current methylation-focused commercial lineage.
- Developer
- Guardant Health
- Intended use
- Monitoring, Mrd, Recurrence Detection
- Cancer scope
- Breast cancer, Colorectal cancer, Lung cancer
- Specimen
- Plasma
- Molecular modality
- DNA methylation
- Current version
- Current methylation-based Guardant Reveal / Infinity-platform lineage
- Evidence context
- 2 structured studies · 3 indexed performance results · 5 sources
Why can reported performance numbers differ? MDI keeps each result attached to its study, population, stage or stratum, test version and source rather than treating performance as a fixed property of the test.